- Home
- OFLX vs YMAB Comparison
OFLX vs YMAB Comparison
Compare OFLX & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- YMAB
- Stock Information
- Founded
- OFLX 1975
- YMAB 2015
- Country
- OFLX United States
- YMAB United States
- Employees
- OFLX N/A
- YMAB N/A
- Industry
- OFLX Industrial Specialties
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- YMAB Health Care
- Exchange
- OFLX Nasdaq
- YMAB Nasdaq
- Market Cap
- OFLX 366.4M
- YMAB 386.7M
- IPO Year
- OFLX 2005
- YMAB 2018
- Fundamental
- Price
- OFLX $34.31
- YMAB $8.61
- Analyst Decision
- OFLX
- YMAB Buy
- Analyst Count
- OFLX 0
- YMAB 10
- Target Price
- OFLX N/A
- YMAB $13.91
- AVG Volume (30 Days)
- OFLX 18.1K
- YMAB 842.3K
- Earning Date
- OFLX 10-29-2025
- YMAB 11-07-2025
- Dividend Yield
- OFLX 3.91%
- YMAB N/A
- EPS Growth
- OFLX N/A
- YMAB N/A
- EPS
- OFLX 1.69
- YMAB N/A
- Revenue
- OFLX $100,700,000.00
- YMAB $85,385,000.00
- Revenue This Year
- OFLX N/A
- YMAB N/A
- Revenue Next Year
- OFLX N/A
- YMAB $13.97
- P/E Ratio
- OFLX $20.00
- YMAB N/A
- Revenue Growth
- OFLX N/A
- YMAB N/A
- 52 Week Low
- OFLX $28.12
- YMAB $3.55
- 52 Week High
- OFLX $57.81
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- OFLX 50.57
- YMAB 81.21
- Support Level
- OFLX $33.32
- YMAB $8.50
- Resistance Level
- OFLX $35.26
- YMAB $8.56
- Average True Range (ATR)
- OFLX 1.20
- YMAB 0.02
- MACD
- OFLX -0.14
- YMAB -0.13
- Stochastic Oscillator
- OFLX 31.73
- YMAB 112.50
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.